Imugene Limited (AU:IMU) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene Limited, a clinical-stage immuno-oncology company, has announced the resignation of Jens Eckstein from its board. Eckstein, who contributed significantly to the company’s growth since 2019, is stepping down to focus on other business ventures. Investors and stakeholders will be watching closely as Imugene continues its ambitious efforts in pioneering cancer treatments.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.